Our mission is focused
Driving Research to End Lung Cancer
Developing groundbreaking dry powder inhalation Aspirin drug to help save lives from lung Cancer
Lung cancer is one of the leading causes of cancer-related deaths worldwide. It is primarily categorized into two main types: Non-Small Cell Lung Cancer (NSCLC), which accounts for approximately 85% of cases, and Small Cell Lung Cancer (SCLC), known for its aggressive nature.
2.2 M
Approximately 2.2 million new cases diagnosed each year – WHO.
a Revolutionary Patented Dry powder inhalation of aspirin
BIOINHALE Pharma is pioneering the development of a revolutionary Dry Powder Inhalation of Aspirin, targeting lung cancer globally.
Worldwide
Lung cancer is one of the most common cancers globally, with approximately 2.2 million new cases diagnosed each year, according to data from the World Health Organization (WHO) and the Global Cancer Observatory (GLOBOCAN) for 2020. It is the leading cause of cancer-related deaths, accounting for around 1.8 million deaths annually.
United States
The American Cancer Society estimates that in 2023, about 238,340 new cases of lung cancer will be diagnosed, and around 127,070 people will die from the disease. Lung cancer represents about 12.3% of all new cancer cases in the U.S. and remains the leading cause of cancer deaths among both men and women.
Europe
Lung cancer incidence and mortality rates vary across Europe, with higher rates in Central and Eastern Europe. The estimated number of new lung cancer cases in Europe is over 470,000 annually, with nearly 400,000 deaths.
Asia
Asia has the highest burden of lung cancer, particularly in countries like China and India, where smoking rates and air pollution are significant risk factors. China alone accounts for more than one-third of the world’s lung cancer cases, with over 800,000 new cases and around 700,000 deaths each year.
Impact
A drug development that revolutionizes lung cancer treatment with targeted therapy
The groundbreaking unique aspects of our Dry Powder Inhalation of Aspirin drug is under pre-clinical trial stage, our commitment to advancing cancer treatment. We are developing a drug-device combination to significantly reduce lung cancer mortality worldwide by offering a more targeted treatment option.
Lung Cancer is more prevalent in men, with 1.2 million new cases annually.
Being one of the top cancer killers, lung Cancer affects 1 million women annually.
In the U.S., there are 330,000 lung Cancer male survivors and 270,000 female.
INVEST OR GET involved
In the Future of Healthcare Innovation.
Pre
Clinical
Trial
Research
At BIOINHALE Pharma, we are pioneering the development of a revolutionary Dry Powder Inhalation of Aspirin designed to target lung cancer at its core. Currently in pre-clinical trials, our research, and development aim to improve drug delivery directly to the lungs targeting cancer cells, offering a new therapeutic approach in the fight against cancer. Discover how we’re advancing cancer care through cutting-edge science and innovation.
01.
Dry
02.
Powder
03.
Inhalation
Current treatment limitations
To fight against lung cancer.
Surgery limitations
Sadly, over two-thirds of lung cancer patients can’t undergo surgery, either due to late-stage diagnosis or other serious health conditions.
Chemotherapy reliance
Most patients must rely on chemotherapy, but the survival rate remains dismally low—fewer than 5% live beyond five years, primarily due to the harsh side effects of current treatments and limited effectiveness.
Treatment resistance
Even with breakthroughs in targeted therapies and immunotherapy, resistance typically develops after one or two years, especially for patients testing positive for PD-L1.
Metastasis complications
Lung cancer spreading beyond the lungs and resulting complications contribute to 50% of all lung cancer deaths.
Targeted Therapy
The Concept of Hope
BIOINHALE Pharma's Dry Powder Inhalation of Aspirin development for lung cancer symbolizes hope through innovative treatments and early detection. By advancing scientific research and enhancing patient outcomes, BIOINHALE Pharma is leading the shift from despair to promising possibilities in lung cancer care."
Proven
Leadership
Experts with decades of experience in pharmaceutical innovation and healthcare technology. With a deep understanding of the regulatory landscape and market dynamics, they are adept at navigating the complexities of the drug development process.
This seasoned leadership not only drives our strategic initiatives but also fosters a culture of innovation and excellence across the organization. Under their guidance, BIOINHALE is poised to deliver groundbreaking solutions that address unmet medical needs and enhance patient care globally.
Innovative Dry Powder Inhalation of Aspirin research
aims to impact globally while treating a substantial portion of U.S. lung cancer patients.
News & Blogs
